Xiaohua Hu

ORCID: 0000-0002-2161-1324
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Lung Cancer Treatments and Mutations
  • Cancer-related molecular mechanisms research
  • Traumatic Brain Injury Research
  • Traumatic Brain Injury and Neurovascular Disturbances
  • Cardiac Arrest and Resuscitation
  • Reconstructive Surgery and Microvascular Techniques
  • RNA modifications and cancer
  • MicroRNA in disease regulation
  • Lung Cancer Research Studies
  • Bone fractures and treatments
  • Cancer Immunotherapy and Biomarkers
  • Wound Healing and Treatments
  • Cancer Genomics and Diagnostics
  • Diabetic Foot Ulcer Assessment and Management
  • Colorectal Cancer Treatments and Studies
  • Lung Cancer Diagnosis and Treatment
  • Burn Injury Management and Outcomes
  • Head and Neck Cancer Studies
  • Ferroptosis and cancer prognosis
  • Stroke Rehabilitation and Recovery
  • RNA Research and Splicing
  • Neuroendocrine Tumor Research Advances
  • HER2/EGFR in Cancer Research
  • Cancer-related gene regulation
  • Immunotherapy and Immune Responses

Beijing Jishuitan Hospital
2015-2025

Capital Medical University
1999-2025

Peking University
2015-2025

Shanghai Zhabei District Shibei Hospital
2022-2025

JiangSu Armed Police General Hospital
2009-2025

Chinese Academy of Agricultural Sciences
2009-2025

Institute of Plant Protection
2025

First Affiliated Hospital of GuangXi Medical University
2016-2024

Guangxi Medical University
2012-2024

Zhejiang Provincial People's Hospital
2007-2024

10.1016/s0140-6736(23)00961-3 article EN The Lancet 2023-07-24

425126 Background: Adjuvant and neoadjuvant immunotherapy have been approved by US FDA to treat early-stage NSCLC. However, the optimal adjuvant treatment, including duration of are unknown. We present interim results a randomized, double-blind, placebo-controlled, phase III trial evaluate efficacy safety perioperative toripalimab plus chemotherapy followed maintenance vs in resectable stage Methods: Patients with II/III NSCLC, without EGFR/ALK alterations for non-squamous were randomly...

10.1200/jco.2023.41.36_suppl.425126 article EN Journal of Clinical Oncology 2023-04-20

Large full-thickness skin lesions have been one of the most challenging clinical problems in plastic surgery repair and reconstruction. To achieve situ regeneration perfect outcomes, we must address two significant obstacles: angiogenesis deficiency inflammatory dysfunction. Recently, black phosphorus has shown great promise wound healing. However, few studies explored bio-effects BP to promote based on its nanoproperties. Here, investigate whether nanosheets positive repair, verified...

10.1021/acsnano.3c11177 article EN cc-by-nc-nd ACS Nano 2024-01-16

Abstract Background Previous studies have shown that a single Coma-Recovery Scale-Revision (CRS-R) assessment can identify high rates of misdiagnosis by clinical consensus. The aim this study was to investigate the proportion consensus compared repeated behavior-scale assessments in patients with prolonged disorders consciousness (DOC). Methods Patients DOC during hospitalization were screened clinicians, and clinicians formed clinical-consensus diagnosis. Trained professionals used CRS-R...

10.1186/s12883-020-01924-9 article EN cc-by BMC Neurology 2020-09-12

The evaluation of childhood trauma is essential for the treatment schizophrenia. short form Childhood Trauma Questionnaire (CTQ-SF) a widely used measure experience in general population. Nevertheless, data regarding psychometric property CTQ-SF assessing patients with schizophrenia are very limited.Two hundred Chinese inpatients completed CTQ-SF, Child Psychological Maltreatment Scale (CPMS), Impact Events Scale-Revised (IES-R), and Dissociative Experiences Scale-II (DES-II). To assess...

10.1371/journal.pone.0208779 article EN cc-by PLoS ONE 2018-12-13

8501 Background: Adjuvant and neoadjuvant immunotherapy have been approved by US FDA to treat early-stage NSCLC. However, the optimal adjuvant treatment, including duration of are unknown. We present interim results a randomized, double-blind, placebo-controlled, Phase III trial evaluate efficacy safety perioperative toripalimab plus chemotherapy followed maintenance vs in resectable stage Methods: Patients with II/III NSCLC, without EGFR/ALK alterations for non-squamous were randomized 1:1...

10.1200/jco.2023.41.16_suppl.8501 article EN Journal of Clinical Oncology 2023-06-01

Due to their distinctive physical and chemical properties as well biological functionalities, multifunctional antibacterial hydrogels possess significant advantages in the treatment of chronic wounds.

10.1039/d4bm00155a article EN cc-by Biomaterials Science 2024-01-01

4110 Background: The phase 3 CARES-310 trial is the first to demonstrate significant progression-free survival (PFS) and overall (OS) benefits with immunotherapy plus an anti-angiogenic tyrosine kinase inhibitor (TKI) over standard TKI as first-line treatment for uHCC. In primary analysis of PFS (data cut-off [DCO], May. 10, 2021) interim OS (DCO, Feb. 8, 2022), improvements were observed camrelizumab (C; anti-PD-1 antibody) + rivoceranib (R; VEGFR2-TKI) vs. sorafenib (S). Here, we report...

10.1200/jco.2024.42.16_suppl.4110 article EN Journal of Clinical Oncology 2024-06-01

Lung squamous cell carcinoma (LUSC) accounts for a significant proportion of lung cancer and there have been few therapeutic alternatives recurrent LUSC due to the lack specific driver molecules. To investigate prospective role lncRNAs in tumorigenesis progression LUSC, aberrantly expressed were calculated based on The Cancer Genome Atlas RNA-seq data. Of 7589 with 504 cases, 884 identified as being (|log2 fold change| >2 adjusted P<0.05) by DESeq R. top 10 highest diagnostic value...

10.18632/oncotarget.18058 article EN Oncotarget 2017-05-22

IntroductionZL-2306-005 is a randomized, double-blind, multicenter phase 3 study evaluating the efficacy and safety of niraparib, poly(adenosine diphosphate-ribose) polymerase inhibitor, as first-line maintenance therapy in Chinese patients with platinum-responsive, extensive-stage SCLC (ES-SCLC).MethodsPatients complete response (CR) or partial (PR) to standardized, platinum-based chemotherapy were randomized 2:1 receive niraparib placebo (300 mg [baseline body weight ≥ 77 kg, platelet...

10.1016/j.jtho.2021.04.001 article EN cc-by Journal of Thoracic Oncology 2021-04-26

Abstract Dual inhibition of vascular endothelial growth factor and epidermal receptor (EGFR) signaling pathways offers the prospect improving effectiveness EFGR-targeted therapy. In this phase 3 study (ClinicalTrial.gov: NCT04028778), 315 patients with treatment-naïve, EGFR- mutated, advanced non-small cell lung cancer (NSCLC) were randomized (1:1) to receive anlotinib or placebo plus gefitinib once daily on days 1–14 per a 3-week cycle. At prespecified final analysis progression-free...

10.1038/s41392-024-01927-9 article EN cc-by Signal Transduction and Targeted Therapy 2024-08-13

Previous studies have shown the prognostic value of stimulation elicited blood-oxygen-level-dependent (BOLD) signal in traumatic patients vegetative state/unresponsive wakefulness syndrome (VS/UWS). However, to best our knowledge, no focused on relevance etiology and level consciousness with disorders (DOC) when explaining relationship between BOLD both outcome variability. We herein propose a study large sample non-traumatic DOC order ascertain variability stimulation-elicited signal. 66...

10.1186/s12916-015-0330-7 article EN cc-by BMC Medicine 2015-04-15

Lipusu is the first commercialized liposomal formulation of paclitaxel and has demonstrated promising efficacy against locally advanced lung squamous cell carcinoma (LSCC) in a small-scale study. Here, we conducted multicenter, randomized, phase 3 study to compare safety cisplatin plus (LP) versus gemcitabine (GP) as first-line treatment or metastatic LSCC.Patients enrolled were aged between 18 75 years, had (clinical stage IIIB, ineligible for concurrent chemoradiation surgery) (Stage IV)...

10.1002/cac2.12225 article EN Cancer Communications 2021-10-26

Wound healing is a dynamic and complex biologic process that could be accelerated by growth factors. To investigate the efficacy of topical recombinant human acidic fibroblast factor (rh-aFGF) treatment in deep partial-thickness burn or skin graft donor sites, we designed randomized, multicenter, double-blind, placebo-controlled clinical trial. The rate, fully healed time were evaluated to assess rh-aFGF application. Laboratory examinations abnormal signs used side toxic effects. results...

10.1111/j.1524-475x.2007.00307.x article EN Wound Repair and Regeneration 2007-11-01

Abstract Background At present, there is no consensus on how to clinically assess localisation sound in patients recovering from coma. We here studied auditory using the patient’s own name as compared a meaningless (i.e., ringing bell). Methods Eighty-six post-comatose diagnosed with vegetative state/unresponsive wakefulness syndrome or minimally conscious state were prospectively included. Localisation of stimulation head eyes orientation toward sound) was assessed bell. Statistical...

10.1186/1471-2377-13-27 article EN cc-by BMC Neurology 2013-03-18

Visual fixation plays a key role in the differentiation between vegetative state/unresponsive wakefulness (VS/UWS) syndrome and minimally conscious state (MCS). However, use of different stimuli changes frequency visual occured patients, thereby possibly affecting accuracy diagnosis. In order to establish standardized assessment patients disorders consciousness (DOC), we compared elicited by mirror,a ball light. was assessed eighty-one post-comatose diagnosed with MCS or VS/UWS. Occurrence...

10.1186/1471-2377-14-147 article EN cc-by BMC Neurology 2014-07-16

Non-small cell lung cancer (NSCLC) has led to the highest cancer-related mortality for decades. To enhance efficiency of early diagnosis and therapy, more efforts are urgently needed reveal origins NSCLC. In this study, we explored effect miR-542-5p in NSCLC with clinical samples vivo models further prospective function though bioinformatics methods. A total 125 tissue were collected, expression was detected by qRT-PCR. The relationship between level clinicopathological features analyzed. on...

10.1186/s12885-017-3646-1 article EN cc-by BMC Cancer 2017-09-19

During autophagy, actin filament networks move and remodel cellular membranes to form autophagosomes that enclose metabolize cytoplasmic contents. Two regulators, WHAMM JMY, participate in autophagosome formation, but the signals linking autophagy assembly are poorly understood. We show that, nonstarved cells, JMY colocalizes with STRAP, a regulator of JMY’s nuclear functions, on nonmotile vesicles no associated networks. Upon starvation, shifts motile, LC3-containing comet tails. LC3...

10.1083/jcb.201802157 article EN cc-by The Journal of Cell Biology 2018-11-12
Coming Soon ...